Skip to main content
OpenTrials

Clinical trial condition

Recurrent Diffuse Large B-Cell Lymphoma

Explore clinical trials studying Recurrent Diffuse Large B-Cell Lymphoma. Study availability and eligibility vary by location and protocol.

60 public trials 19 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Diffuse Large B-Cell Lymphoma trial results

Completed

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

NCT01251575

Conditions
Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma, +67 more
Locations
  • Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
  • Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
  • VA Puget Sound Health Care System Seattle, Washington, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details
Active, Not Recruiting

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

NCT03321643

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +14 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
View Trial Details
Active, Not Recruiting

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT01955499

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +21 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
View Trial Details
Active, Not Recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

NCT03038672

Conditions
ALK-Positive Large B-Cell Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +53 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Moffitt Cancer Center-International Plaza Tampa, Florida, United States
View all 33 locations
View Trial Details

Related conditions